Review outlines promise and limits of GI proteomics in pets
Bottom line
A new review in Animals maps where proteomics stands in canine and feline gastrointestinal disease research, and the takeaway is promising but cautious: the science is moving, clinical use isn’t there yet. Jane Yu of City University of Hong Kong and Craig Ruaux of the University of Minnesota reviewed the veterinary literature through May 2026 and found that published proteomic studies in companion-animal gastroenterology are still limited, with most work centered on chronic enteropathy and focused on early-stage biomarker discovery rather than validated tests ready for practice. The review says proteomics is helping researchers study disease mechanisms and identify candidate biomarkers in samples such as serum, feces, and intestinal tissue, but major knowledge gaps remain around standardization, verification, and real-world clinical translation. (mdpi.com)
Why it matters: For veterinary professionals, the paper is a useful reality check. Proteomics may eventually improve diagnosis, monitoring, and treatment-response assessment in GI disease, especially where today’s biomarkers lack sensitivity or specificity, but the review argues the field is still in the discovery phase in dogs and cats. That matters in chronic enteropathy, where clinicians still rely on a mix of history, exclusion testing, imaging, histopathology, and imperfect laboratory markers. Recent work in canine chronic inflammatory enteropathies has identified possible plasma biomarker candidates, but those findings still need broader validation before they can change case management. (mdpi.com)
What to watch: Expect the next phase to focus on larger, controlled validation studies and on whether any candidate protein signatures can outperform or complement current GI diagnostics in practice. (mdpi.com)
Key facts
- Study type
- Review
- Journal
- Animals
- Authors
- Jane Yu and Craig Ruaux
- Institutional affiliations
- City University of Hong Kong and University of Minnesota
- Literature reviewed through
- May 2026
- Main focus
- Proteomics in canine and feline gastrointestinal disease
- Strongest area of published work
- Chronic enteropathy
- Main takeaway
- Promising for biomarker discovery, but not ready for routine clinical use
- Key limitation
- Studies remain sparse, with major gaps in standardization, verification, and clinical translation
A newly published review in Animals takes stock of proteomics in gastrointestinal disease research for dogs and cats and lands on a familiar but important conclusion: the technology has real potential, but veterinary medicine is still a long way from routine clinical application. Reviewing the literature available through May 2026, Jane Yu and Craig Ruaux found that proteomic studies in companion-animal gastroenterology remain sparse, with the strongest concentration of work in chronic enteropathy and biomarker discovery. (mdpi.com)
That framing matters because proteomics has been discussed for years as a way to move beyond blunt or nonspecific biomarkers. In broader veterinary medicine, mass spectrometry-based proteomics has been used to study blood, saliva, urine, feces, tissues, and other sample types, but adoption has lagged behind human medicine, in part because companion animals still have more limited reference databases and fewer validated pipelines for turning protein signals into clinically useful tests. A 2024 Frontiers paper on healthy adult dog plasma underscored the same point: building reference proteomes is a prerequisite for disease-specific biomarker work, and even sample-prep methods such as depletion of abundant proteins remain technically challenging in dogs. (pubmed.ncbi.nlm.nih.gov)
In the GI space specifically, the new review says current studies have examined serum, feces, and intestinal tissues to better understand pathophysiology and identify candidate biomarkers for diagnosis, monitoring, and treatment response. The authors report that, after screening the literature, only a small number of canine studies met inclusion criteria, highlighting how early the field still is. Their central conclusion is that proteomics is advancing understanding of diseases such as chronic enteropathy, but substantial verification and validation work is still needed before any biomarker can be relied on in everyday companion-animal practice. (mdpi.com)
The broader literature supports that caution. In cats with chronic enteropathies, serum proteome profiling has shown that inflammatory and gut-injury signals can be detected in blood, suggesting biological plausibility for future diagnostics. In dogs, newer research has identified proteins including properdin, transcortin, and HGFAC as potential plasma biomarkers in chronic inflammatory enteropathies, with investigators positioning HGFAC as a possible disease-associated marker and even a therapeutic lead. Still, these are small-cohort studies, and the step from candidate marker to robust clinical assay is the hard part. (pubmed.ncbi.nlm.nih.gov)
Industry and academic commentary around veterinary omics has been moving in the same direction. Reviews of clinical veterinary proteomics have consistently argued that the technology is powerful for pathway discovery and biomarker hunting, while also warning that data interpretation, species-specific reference limitations, and assay standardization remain major barriers. That’s especially relevant in GI disease, where chronic enteropathy is heterogeneous and current diagnostic workups already combine multiple imperfect tools rather than a single decisive test. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinarians, this review is less about an immediate practice change and more about setting expectations. Proteomics could eventually help distinguish disease subtypes, identify earlier or less invasive biomarkers, and track response to diet, immunomodulation, or other therapies. But for now, it’s best understood as a research engine, not a ready-to-order diagnostic category. That distinction matters when talking with pet parents about chronic GI cases, where interest in “precision” tools is high, but evidence for routine use still trails the promise. (mdpi.com)
The review also points toward where the field likely needs to go next: better standardization of sample collection and analytic workflows, stronger healthy-reference datasets in dogs and cats, and larger prospective cohorts that test whether candidate protein signatures add value beyond existing diagnostics. If those pieces come together, proteomics could become more relevant not just for understanding GI disease biology, but for shaping real clinical decision-making. (mdpi.com)
What to watch: The key next milestone will be validation, not discovery, especially studies that test whether proteomic markers can reliably separate GI disease phenotypes or predict treatment response in larger, clinically diverse populations. (mdpi.com)